Folic acid 5mg tablets for use during pregnancy

Published Last updated See all updates

SPS PGD template for the supply of folic acid 5mg tablets to reduce risk of neural tube defect or compensate for increased folate demand during pregnancy.

Provenance

Developed by SPS and NHS England, reviewed by the Royal College of Obstetrics and Gynaecology (RCOG), with the support of specialists working within clinical practice for medicines commonly supplied for the prevention of complications in pregnancy.

Planned update to this template

An update is to be made to the folic acid 5mg tablets for use during pregnancy PGD template following the publication of the updated BHIVA guidelines on the management of HIV in pregnancy and the postpartum period (2025).

Reflecting the updated guidance this revision will remove the inclusion criteria relating to individuals living with HIV who are planning to conceive/do conceive whilst taking dolutegravir.

It is expected that the updated PGD template will be published on this page by the end of October 2025.

PGD template attachment

The template PGD is attached below to download and use in conjunction with our implementation advice.

Safety in Pregnancy, Templates, Patient Group Directions

All PGD templates

National PGD templates

National PGD templates are developed with experts for clinical specialties. They reduce duplication and variation, and improve consistency of care.

Update history

  1. New section added regarding planned update to this PGD template.
  1. Updated template published (changes detailed within document)
  1. Version 1.0 removed as expired
  1. Version 2.0 for use from 1st February 2025 published
  1. Title, URL and summary amended.
  1. Published

Print this page